APPL1 Is a Prognostic Biomarker and Correlated with Treg Cell Infiltration Via Oxygen-Consuming Metabolism in Renal Clear Cell Carcinoma

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2023 Feb 27

PMID 36846720

Authors

Ming Yang

Chuhui Gong

Kangping Song

Ning Huang

Honghan Chen

Hui Gong

Yu Yang

Shujing Guo

Hengyi Xiao

Affiliations

Soon will be listed here.

Abstract

Kidney renal clear cell carcinoma (KIRC) is one of the most hazardous tumors in the urinary system. The regulation of oxygen consumption in renal clear cell carcinoma is a consequence of adaptive reprogramming of oxidative metabolism in tumor cells. APPL1 is a signaling adaptor involved in cell survival, oxidative stress, inflammation, and energy metabolism. However, the correlation of APPL1 with regulatory T cell (Treg) infiltration and prognostic value in KIRC remain unclear. In this study, we comprehensively predicted the potential function and prognostic value of APPL1 in KIRC. For KIRC patients, relatively low expression of APPL1 was associated with high degree of metastasis, pathological stage, and shorter overall time or poor prognosis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses suggested that low expression of APPL1 may be adapted to the malignant progression of tumors via affecting oxygen-consuming metabolism. In addition, the expression level of APPL1 was negatively correlated with Treg cell infiltration and chemotherapy sensitivity, which indicated that APPL1 may regulate the tumor immune infiltration and chemotherapy resistance by decrease oxygen-consuming metabolic process in KIRC. Therefore, APPL1 may become one of the important prognostic factors, and it may serve as a candidate prognostic biomarker in KIRC.

Citing Articles

Evaluation of the diagnostic utility of immune microenvironment-related biomarkers in endometriosis using multidimensional transcriptomic data.

Tu Q, Zhao R, Lu N J Assist Reprod Genet. 2024; 41(11):3213-3223.

PMID: 39316330 PMC: 11621284. DOI: 10.1007/s10815-024-03261-z.

Mitochondrial energy metabolism correlates with an immunosuppressive tumor microenvironment and poor prognosis in esophageal squamous cell carcinoma.

Zhang Z, Jin G, Zhao J, Deng S, Chen F, Wuyun G Comput Struct Biotechnol J. 2023; 21:4118-4133.

PMID: 37664173 PMC: 10474161. DOI: 10.1016/j.csbj.2023.08.022.

Integrated transcriptome analysis identifies APPL1/RPS6KB2/GALK1 as immune-related metastasis factors in breast cancer.

Chen G, Zhang K, Liang Z, Zhang S, Dai Y, Cong Y Open Med (Wars). 2023; 18(1):20230732.

PMID: 37273920 PMC: 10238809. DOI: 10.1515/med-2023-0732.

References

Tan Y, You H, Coffey F, Wiest D, Testa J . Appl1 is dispensable for Akt signaling in vivo and mouse T-cell development. Genesis. 2010; 48(9):531-9. PMC: 2944914. DOI: 10.1002/dvg.20657. View

Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B . APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell. 2004; 116(3):445-56. DOI: 10.1016/s0092-8674(04)00117-5. View

Meskawi M, Sun M, Trinh Q, Bianchi M, Hansen J, Tian Z . A review of integrated staging systems for renal cell carcinoma. Eur Urol. 2012; 62(2):303-14. DOI: 10.1016/j.eururo.2012.04.049. View

Shuch B, Amin A, Armstrong A, Eble J, Ficarra V, Lopez-Beltran A . Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2014; 67(1):85-97. DOI: 10.1016/j.eururo.2014.04.029. View

Wettersten H . Reprogramming of Metabolism in Kidney Cancer. Semin Nephrol. 2020; 40(1):2-13. DOI: 10.1016/j.semnephrol.2019.12.002. View

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Sharpe A, Pauken K . The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2017; 18(3):153-167. DOI: 10.1038/nri.2017.108. View

Sayeed M, Gautam S, Verma D, Afshan T, Kumari T, Srivastava A . A collagen domain-derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms. J Biol Chem. 2018; 293(35):13509-13523. PMC: 6120198. DOI: 10.1074/jbc.RA118.001801. View

10.

Schodel J, Grampp S, Maher E, Moch H, Ratcliffe P, Russo P . Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol. 2015; 69(4):646-657. PMC: 5012644. DOI: 10.1016/j.eururo.2015.08.007. View

11.

Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel C . HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017; 8(1):1769. PMC: 5701259. DOI: 10.1038/s41467-017-01965-8. View

12.

Liu Y, Zhang C, Zhao L, Du N, Hou N, Song T . APPL1 promotes the migration of gastric cancer cells by regulating Akt2 phosphorylation. Int J Oncol. 2017; 51(4):1343-1351. DOI: 10.3892/ijo.2017.4121. View

13.

Wettersten H, Abu Aboud O, Lara Jr P, Weiss R . Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017; 13(7):410-419. DOI: 10.1038/nrneph.2017.59. View

14.

Motoshima T, Miura Y, Wakigami N, Kusada N, Takano T, Inoshita N . Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma. Med Mol Morphol. 2017; 51(1):57-63. DOI: 10.1007/s00795-017-0174-7. View

15.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

16.

Diaz-Montero C, Rini B, Finke J . The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020; 16(12):721-735. DOI: 10.1038/s41581-020-0316-3. View

17.

Zhu Q, Cai M, Weng D, Zhao J, Pan Q, Wang Q . PD-L1 expression patterns in tumour cells and their association with CD8 tumour infiltrating lymphocytes in clear cell renal cell carcinoma. J Cancer. 2019; 10(5):1154-1161. PMC: 6400669. DOI: 10.7150/jca.29052. View

18.

Ella-Tongwiis P, Makanga A, Shergill I, Hughes S . Optimisation and validation of immunohistochemistry protocols for cancer research. Histol Histopathol. 2021; 36(4):415-424. DOI: 10.14670/HH-18-317. View

19.

Geissler K, Fornara P, Lautenschlager C, Holzhausen H, Seliger B, Riemann D . Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology. 2015; 4(1):e985082. PMC: 4368143. DOI: 10.4161/2162402X.2014.985082. View

20.

Iliopoulos O . Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006; 24(35):5593-600. DOI: 10.1200/JCO.2006.08.8948. View